MDxHealth S.A. operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares MDxHealth S.A. with three other
miscellaneous service companies in Europe:
Kiadis Pharma NV
sales of 17.50 million Euros [US$21.21 million]
Bioinvent International AB
(147.37 million Swedish Kronor [US$17.66 million]
of which 52%
was Revenue from collaboration agreements as), and
Tissue Regenix Group PLC
based in UNITED KINGDOM
(£12.83 million [US$17.89 million]
MDxHealth S.A. reported sales of 16.09 million Euro (US$19.50 million)
December of 2020.
increase of 52.6%
versus 2019, when the company's sales were 10.54 million Euro.
Despite this increase, sales are still
below the level achieved in 2018, when MDxHealth S.A.
reported sales of 24.10 million Euro.
The sales level in 2020 was fairly close to the level five years ago: in 2015, MDxHealth S.A. had sales
of 15.99 million Euro.